Logo

RBOT

Vicarious Surgical Inc.

RBOT

Vicarious Surgical Inc. • NYSE
$3.01 ▲ 11.90% (+0.32)
Market Cap $17.74 M
52w High $19.00
52w Low $2.44
Dividend Yield 0%
P/E -0.33
Volume 89.45K
Outstanding Shares 5.89M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $11.151M ▼ $-11.058M ▲ 0% $-1.86 ▲ $-10.706M ▲
Q2-2025 $0 $13.519M ▼ $-13.215M ▲ 0% $-2.23 ▲ $-13.106M ▲
Q1-2025 $0 $15.747M ▲ $-15.394M ▼ 0% $-2.6 ▼ $-15.378M ▼
Q4-2024 $0 $14.436M ▼ $-13.926M ▲ 0% $-2.36 ▲ $-13.384M ▲
Q3-2024 $0 $17.755M $-17.091M 0% $-2.9 $-16.584M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $13.414M ▼ $29.347M ▼ $15.259M ▼ $14.088M ▼
Q2-2025 $23.963M ▼ $40.89M ▼ $17.827M ▼ $23.063M ▼
Q1-2025 $37.362M ▼ $55.052M ▼ $20.976M ▼ $34.076M ▼
Q4-2024 $49.097M ▼ $67.719M ▼ $21.021M ▼ $46.698M ▼
Q3-2024 $60.864M $80.616M $22.734M $57.882M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.058M ▲ $-10.42M ▲ $9.654M ▼ $25.907K ▲ $-746K ▼ $-10.537M ▲
Q2-2025 $-13.215M ▲ $-13.492M ▼ $14.788M ▲ $23.935K ▲ $1.311M ▲ $-13.492M ▼
Q1-2025 $-15.394M ▼ $-11.768M ▲ $4.613M ▼ $16.999K ▲ $-7.138M ▼ $-11.773M ▲
Q4-2024 $-13.926M ▲ $-11.788M ▲ $14.45M ▲ $6K ▲ $2.668M ▲ $-11.968M ▲
Q3-2024 $-17.091M $-12.689M $-492K $0 $-13.181M $-12.673M

Five-Year Company Overview

Income Statement

Income Statement Vicarious Surgical is still a pure development-stage company with no product revenue yet. The income statement is driven almost entirely by research, engineering, and overhead costs, which result in steady operating losses each year. Those losses have been relatively stable, not exploding, but also not yet narrowing in a decisive way. The brief move into positive net income a couple of years ago looks more like an accounting or one‑time item than a sign of a sustainable profit engine. Overall, the business remains firmly pre-revenue and dependent on future commercialization to change the pattern.

Balance Sheet

Balance Sheet The balance sheet is small and has been gradually shrinking as cash is used to fund development. Cash once made up the bulk of total assets but has come down over time, reflecting ongoing cash burn. Equity has also trended lower, which is normal for a company that is spending more than it earns, but it leaves a thinner cushion against future setbacks. Debt is present but modest relative to total assets, so leverage is not the central concern; instead, the main issue is how long existing cash can support operations before additional funding is needed. Any recent capital raises help, but the overall profile still looks like an early-stage company with a finite financial runway.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, which is typical for a pre-revenue medical device developer. The company spends cash on salaries, engineering, clinical readiness, and overhead, and there is no offsetting product income yet. Capital spending on equipment and facilities has been relatively modest, so most of the cash burn is tied directly to running and advancing the R&D program rather than heavy infrastructure build-out. Free cash flow has been negative for several years in a row, reinforcing that the business currently consumes cash and relies on external financing to keep progressing toward commercialization.

Competitive Edge

Competitive Edge Vicarious Surgical is trying to carve out a niche in a highly competitive field dominated by large, entrenched robotics players. Its proposed edge is a single‑port system that mimics human arm movement and aims to be more compact and potentially more affordable than legacy robots. The FDA Breakthrough Device designation and a sizable patent portfolio give the company some regulatory and intellectual property advantages, and focusing on specific abdominal procedures offers a clear initial target market. At the same time, the company has not yet commercialized its system, faces powerful competitors with deep pockets, and has already experienced delays in its clinical and regulatory timelines. For now, its competitive position is based on promise and technology rather than proven market share.

Innovation and R&D

Innovation and R&D Innovation is the heart of Vicarious Surgical. The company is developing a human‑like robotic system, immersive visualization, and a single‑incision approach that, if successful, could reshape how certain abdominal surgeries are performed. A large and active patent portfolio supports this effort and may create barriers for copycats. The firm has invested heavily in R&D for years, though it has recently trimmed some development spending to manage cash, which can help extend runway but may also slow the pace of progress. Regulatory plans now point to an FDA submission target a few years out, and a recent leadership transition adds another variable to execution. In short, the R&D story is ambitious and technically differentiated but still in the proving phase.

Summary

Vicarious Surgical is an early-stage surgical robotics company with bold technology goals and a clear clinical focus, but it remains pre-revenue and pre-commercial. The financial picture shows a classic development story: recurring losses, steadily negative cash flow, a shrinking but still functional cash base, and limited use of debt. Its potential strength lies in differentiated robotics, strong intellectual property, and regulatory recognition through Breakthrough Device status. Its main risks center on execution: completing system design, running successful trials, securing regulatory clearance on an extended timeline, and obtaining enough capital to bridge that gap in a market dominated by large incumbents. The company’s future will largely be determined by how well it converts its technical vision into a cleared, adoptable product before financial resources become too tight.

NEWS

November 19, 2025 · 4:15 PM UTC

Vicarious Surgical to Participate in the Piper Sandler 37th Annual Healthcare Conference

Read more

November 12, 2025 · 4:15 PM UTC

Vicarious Surgical Reports Third Quarter 2025 Financial Results

Read more

November 6, 2025 · 6:13 PM UTC

Vicarious Surgical to Report Third Quarter 2025 Financial Results on November 12, 2025

Read more

October 8, 2025 · 7:00 AM UTC

Vicarious Surgical Announces Pricing of $5.9 Million Registered Direct Offering

Read more

September 25, 2025 · 4:15 PM UTC

Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

Read more